Biodesix, Inc. (NASDAQ:BDSX) CEO Sells $76,967.20 in Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Biodesix Trading Up 2.4 %

BDSX stock opened at $0.96 on Friday. The firm has a fifty day moving average price of $1.24 and a 200 day moving average price of $1.49. Biodesix, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The firm has a market cap of $140.09 million, a PE ratio of -2.47 and a beta of 1.06.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC grew its holdings in shares of Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares in the last quarter. HighTower Advisors LLC grew its holdings in shares of Biodesix by 17.1% in the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after purchasing an additional 22,500 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Biodesix by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after purchasing an additional 22,623 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Biodesix in the third quarter valued at $262,000. Finally, Stephens Inc. AR purchased a new position in shares of Biodesix in the fourth quarter valued at $303,000. 20.96% of the stock is owned by hedge funds and other institutional investors.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.